GlassScriptPhysician profile
Paul Ryan Bader
NPI 1407484900
$7,393.31
in general payments reported to CMS, 2019-2025
38 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $844 · 2022: $1,306 · 2023: $1,918 · 2024: $1,847 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,093 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,093.31 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,191.63 | 2021-2025 | |
| Novo Nordisk INC | $829.54 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $671.99 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $519.56 | 2021-2024 | Evenity, Prolia, Otezla |
| Pfizer INC. | $460.20 | 2022-2025 | |
| Lilly USA, LLC | $436.17 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $352.37 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.37 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $302.79 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.52 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Janssen Pharmaceuticals, INC | $234.10 | 2021-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $212.57 | 2021-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $179.92 | 2022 | |
| Esperion Therapeutics, INC. | $152.99 | 2021-2025 | Nexletol |
| Jazz Pharmaceuticals INC. | $150.00 | 2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $136.82 | 2022-2025 | Vyepti |
| Gilead Sciences, INC. | $120.86 | 2023 | Biktarvy |
| Sanofi-Aventis U.S. LLC | $118.00 | 2022-2023 | |
| Exact Sciences Corporation | $105.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bausch Health US, LLC | $89.53 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $62.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.19 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $59.98 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $56.59 | 2025 | Voquezna |
| Antares Pharma, INC. | $54.82 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Alnylam Pharmaceuticals INC. | $38.07 | 2024 | Givlaari |
| Xeris Pharmaceuticals, INC. | $36.36 | 2023-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $30.78 | 2021-2023 | Belsomra |
| Astellas Pharma US INC | $26.24 | 2025 | Veozah |
| Corcept Therapeutics | $23.43 | 2025 | Korlym |
| Inogen, INC. | $22.64 | 2022 | |
| Axsome Therapeutics, INC. | $20.88 | 2024 | Auvelity |
| Dynavax Technologies Corporation | $15.26 | 2024 | Heplisav-B |
| E.R. Squibb & Sons, L.L.C. | $14.35 | 2025 | Camzyos |
| Halozyme INC | $14.20 | 2023 | |
| Corium, LLC | $13.46 | 2023 | Adlarity |
| Neurocrine Biosciences, INC. | $12.20 | 2021 | |
| Eisai INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.